Baricitinib

From WikiMD.org
Jump to navigation Jump to search

Baricitinib

Baricitinib (pronounced as baa-ri-si-ti-nib) is a medication used for the treatment of rheumatoid arthritis and COVID-19. It is an Janus kinase inhibitor that interferes with the JAK-STAT signaling pathway, a type of protein coding communication process that transmits information from chemical signals outside the cell, through the cell membrane, and into gene promoters on the DNA in the cell nucleus.

Etymology

The name "Baricitinib" is derived from the class of drugs it belongs to, known as Janus kinase inhibitors. The "bari" part of the name is a prefix used in pharmacology to denote drugs that inhibit the Janus kinase family of enzymes. The "citinib" suffix is common among kinase inhibitors.

Usage

Baricitinib is used primarily for the treatment of moderate to severe rheumatoid arthritis in adults who have not responded well to one or more tumor necrosis factor (TNF) antagonist therapies. It is also used in combination with remdesivir in the treatment of COVID-19.

Related Terms

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski